Concert Pharmaceuticals Presents Positive Data From Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate For The Treatment of Spasticity
October 13, 2014 at 07:07 AM EDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, ...
